Huperzine

non-nutrient_non-botanical
Browse products

Huperzine A is a naturally occurring alkaloid extracted primarily from Chinese club moss (Huperzia serrata). Despite its plant origin, its isolated form is classified as a non-nutrient and non-botanical ingredient due to its specific chemical structure and targeted pharmacological action. Its primary mechanism involves inhibiting acetylcholinesterase, which is the enzyme responsible for breaking down acetylcholine in the brain. Acetylcholine is a vital neurotransmitter for various cognitive processes, including memory, learning, and attention. By inhibiting the enzyme that breaks it down, Huperzine A increases and prolongs the availability of acetylcholine in the synaptic cleft to support cholinergic neurotransmission. This mechanism underlies its potential benefits for several aspects of cognitive function. Beyond its role in acetylcholine regulation, Huperzine A may possess neuroprotective properties by potentially reducing oxidative stress and protecting neurons from damage. Its long duration of action and relatively high bioavailability make it a common subject of research for cognitive support, particularly regarding age-related cognitive decline.

Natural sources
Chinese club moss (Huperzia serrata)

No public comparison lists found.

Optimal Dosage
Minimum50 mcg
Maximum200 mcg
Safety & Toxicity
Upper Limit (UL)200 mcg
Toxicity Threshold300 mcg
Toxicity EffectNausea, restlessness, increased blood pressure
6 safety notes
  • Individuals with heart conditions (e.g., bradycardia), asthma, epilepsy, or obstructive lung diseases should use with caution or avoid.
  • May increase stomach and intestinal secretions, potentially worsening ulcers or blockages.
  • May cause urinary tract obstruction.
  • Not recommended for pregnant or breastfeeding women.
  • Discontinue use if side effects occur or worsen.
  • Consult a healthcare professional before use, especially if on medications.
Goals
Brain Health
Brain Health
Impact
High effect
Typical dose:50–400 mcg
Huperzine A is an acetylcholinesterase inhibitor, meaning it stops the enzyme that breaks down acetylcholine, a key neurotransmitter for memory. This produces a noticeable, acute boost in cognitive function. Due to its potency and mechanism, it requires cycling and is not a foundational supplement.

Study evidence

17 studies

Huperzine A may improve cognitive symptoms and daily functioning in people with Alzheimer disease, but the evidence is limited by study quality. The supplied research does not establish broader brain protection, prevention of dementia, or cognitive benefits in healthy adults.

View goal
Cognitive Support
Cognitive Support
Impact
High effect
Typical dose:50–400 mcg
Huperzine A effectively boosts the neurotransmitter acetylcholine by blocking its breakdown. This makes it a powerful tool for short-term enhancement of focus and memory. However, due to its long half-life and potency, it is not a foundational supplement and requires cycling to avoid side effects and downregulation.

Study evidence

22 studies

Huperzine A has shown potential to improve cognition in Alzheimer’s disease, but inconsistent trial results and weaknesses in the research limit confidence. The available evidence does not establish a reliable benefit for everyday cognitive enhancement or for other forms of cognitive impairment.

View goal
Mental Focus
Mental Focus
Impact
High effect
Typical dose:50–200 mcg
Huperzine A is an acetylcholinesterase inhibitor, meaning it prevents the enzyme that breaks down acetylcholine. This leads to a rapid and significant increase in acetylcholine levels, acutely enhancing focus and memory. Due to its potency and long half-life, it is best used tactically and requires cycling to avoid downregulation.

Study evidence

No published studies for this goal yet.

View goal
Productivity Boost
Productivity Boost
Impact
High effect
Typical dose:50–400 mcg
Huperzine A is a powerful acetylcholinesterase inhibitor, which increases levels of the neurotransmitter acetylcholine, crucial for learning and concentration. Due to its long half-life and potency, it is best used cyclically (e.g., a few days on, a few days off) for specific demanding tasks or projects rather than for daily, continuous supplementation.

Study evidence

1 study

The supplied research does not support Huperzine as a productivity booster. Testing in physically trained adults found no improvement in mental performance during exercise, and that narrow setting cannot establish whether it affects everyday concentration, work output or longer-term cognitive performance.

View goal

Studies

Research connections will load here.
Sources

Up to five highest-ranked published examples per goal. Study counts and charts include all published studies for the connection.

  1. Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis.
    Xing SH; Zhu CX; Zhang R; An L · Evidence-based complementary and alternative medicine : eCAM · 2014
    Meta-analysis825 participants10 studies pooledBrain HealthCognitive Support
  2. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G · Zhonghua yi xue za zhi · 2002
    Randomized trial202 participantsBrain HealthCognitive Support
  3. Huperzine A associated with improved early postoperative cognitive function after neurosurgery under general anesthesia: a randomized clinical trial.
    Zhang Z; Shen Y; Li J; Tang Y; Zhou P; Ying T; Mo R; Ru Z; Zhao G; Zhu J; Li S; Zhao H · International journal of surgery (London, England) · 2026
    Randomized trial123 participantsCognitive SupportBrain Health
  4. Treatment with Huperzine A improves cognition in vascular dementia patients.
    Xu ZQ; Liang XM; Juan-Wu; Zhang YF; Zhu CX; Jiang XJ · Cell biochemistry and biophysics · 2012
    Randomized trial78 participantsBrain Health
  5. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
    Gul A; Bakht J; Mehmood F · Journal of the Chinese Medical Association : JCMA · 2019
    Randomized trial100 participantsBrain Health
  6. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.
    Zheng W; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Sun F; D'Arcy C; Meng X; Xiang YT · Human psychopharmacology · 2017
    Meta-analysis1,117 participants12 studies pooledCognitive Support
  7. [Drug evaluation of huperzine A in the treatment of senile memory disorders].
    Zhang RW; Tang XC; Han YY; Sang GW; Zhang YD; Ma YX; Zhang CL; Yang RM · Zhongguo yao li xue bao = Acta pharmacologica Sinica · 1992
    Randomized trial56 participantsCognitive Support
  8. Effect of Huperzine A on Cognitive Function and Perception of Effort during Exercise: A Randomized Double-Blind Crossover Trial.
    Wessinger CM; Inman CL; Weinstock J; Weiss EP · International journal of exercise science · 2025
    Randomized trial15 participantsProductivity Boost